USCOM LIMITED — Investor Presentation 2016

Jun 1, 2016

**Uscom

(UCM)
–
Global
Medical
Devices**

Revenue
growth June
2016

Rob Phillips PhD(med), MPhil(med), FASE, DMU(cardiol) Associate Professor, Critical Care Research Group, School of Medicine, The University of Queensland Uscom Executive Chairman/CEO

The Measure of Life

Disclaimer

This
presenta,on
is
intended
to
provide
a
general
outline
only
and
is
not
intended
to
be
a
defini,ve statement
on
the
subject
ma9er.
The
informa,on
in
this
presenta,on,
whether
wri9en
or
verbal,
has been
prepared
without
taking
into
account
the
commercial,
financial
or
other
needs
of
any
individual or
organisa,on.

While
Uscom
(the
"Company”)
has
taken
due
care
in
compiling
the
informa,on,
neither
the
Company nor
its
officers
or
advisors
or
any
other
person
warrants
the
accuracy,
reliability,
completeness
or ,meliness
of
the
informa,on
or
guarantees
the
commercial
or
investment
performance
of
the Company.
Certain
informa,on
may
relate
to
protected
intellectual
property
rights
owned
by
Uscom. By
viewing
this
presenta,on
the
viewer
accepts
the
terms
of
the
Company
NDA. The
informa,on
does
not
cons,tute
advice
of
any
kind
and
should
not
be
relied
on
as
such.
Investors must
make
their
own
independent
assessment
of
the
Company
and
undertake
such
addi,onal enquiries
as
they
deem
necessary
or
appropriate
for
their
own
investment
purposes.
Any
and
all
use of
the
informa,on
is
at
your
own
risk.

2

Uscom

“Uscom has acquired global assets to ensure reliable revenue growth for investors for the coming decade.”

3

Uscom
–
Medical
devices
the
experts
use

==> picture [701 x 395] intentionally omitted <==

4

Business Background § Premium
noninvasive
cardiovascular
and
pulmonary
monitoring
devices § Addressing
the
growing
threat
of
superbugs,
heart
failure,
hypertension
and
asthma § Validated,
clinically
accepted,
cost
and
life
saving
devices
with
cri,cal
applica,ons § Aggressive
global
growth
strategy

§ IP
protected
with
regulatory
approvals

§ Uscom
BP+
and
SpiroSonic
for
market
FY
2017 § +50%
growth
from
USCOM
1A,
with
BP+
and
SpiroSonic
revenue
ahead

Corporate § ASX listed (UCM) § Headquartered in Sydney § Market cap of $20m § 100m shares on issue § Rob Phillips, Founder and CEO, holds 20% of company		Board & Management § Rob Phillips, Chairman & CEO § Sheena Jack, Director (HCF, Money,me Health) § Chris,an Bernecker, Director (Stream) § David He, Director (J&J, McKinseys) § Nick Schicht, General Manager		Financials § Sales +59% 2015 § Revenue +48% 2015 ($2+m) § Cash consump,on - $1m § Gross Margins ~ 78% § Cash ~ $0.6m

5

• Uscom
  Annual
  report

Strategic growth

==> picture [528 x 93] intentionally omitted <==

----- Start of picture text -----

Uscom Pulsecor Thor
Uscom
Limited Limited Kft
Limited
$50m $50m $50m
2016
2010 2013 2015
----- End of picture text -----

Rapidly
strengthening
balance
sheet Acquisi5ve,
strategic
and
diversified
en5ty Acquired
and
integrated
Pulsecor
(2013)
and
Thor
(2015) Debt
free
acquisi5ons
–
scrip,
raising
and
opera5ons Scien5fic,
opera5onal
and
strategic
synergy New
product
developments
funded
from
opera5ons Two
new
product
suites
ready
for
revenue/market UK
en5ty
established Budapest
manufacturing
profitable Preparing
for
volume
manufacture
of
BP+
and
SpiroSonic

Uscom
–
Devices
the
experts
use

6

Uscom Recognition

Company
of
the
Year,
2014 Johnson
&
Johnson
InnovaCon
Industry
Excellence
Awards “A
milestone
driven,
rapidly
growing
global medical
device
company,
with
real
products, real
revenue,
real
growth
and
an
aggressive growth
strategy”

==> picture [368 x 47] intentionally omitted <==

==> picture [204 x 90] intentionally omitted <==

7

Uscom
–
Devices
the
experts
use

Products and Market

MulCple
high
fidelity
noninvasive
digital
medical
devices

**Fluid,

Sepsis**

**&

Heart
Failure**

• § US
  1.3bn
  market[

• ]

• § CAGR
  of
  7.6%[

• ]

• § CE,
  FDA,
  TGA,
  CFDA

Hypertension
& Vascular
Health

• § US
  1.7bn
  market[
  *]

• § CAGR
  of
  11.5%[

• ]

• § CE,
  FDA,
  TGA

**COPD &

Asthma**

• § US
  400m
  market[
  *]

• § CAGR
  of
  6.5%[

• ]

• § CE,
  TGA,
  FDA

USCOM
1A Cardiac
Output
Monitoring

BP+ Blood
Pressure
Monitoring

SpiroSonic Pulmonary
Monitoring

• Source:
  MedTech
  Insight;
  Transparency
  Market
  Research

==> picture [131 x 105] intentionally omitted <==

==> picture [116 x 118] intentionally omitted <==

_**Uscom

–
Devices
the
experts
use**_

==> picture [215 x 147] intentionally omitted <==

8

Products - USCOM 1A

Heart failure, hypertension, sepsis, fluid Non invasive, accurate, compact, platform technology

Accurate cardiac output Cardiac stroke volume Systemic vascular resistance Left + right heart measurement

==> picture [285 x 232] intentionally omitted <==

Works with all other hospital equipment Intuitive touch screen Real time data Platform technology with multiple uses

Non invasive, real time, beat-to-beat haemodynamics

9

Uscom
–
Devices
the
experts
use

Products - USCOM 1A

USCOM study in pediatric sepsis

-46% Mortality!

Lives Saved in Study!

==> picture [370 x 255] intentionally omitted <==

==> picture [188 x 250] intentionally omitted <==

Septic Shock Mortality in King Chulalongkorn Memorial Hospital – Uscom use began in 2013.

Thongnual C, Hantragool S, Samransamriatkit R. Efficacy of non-invasive cardiac monitoring (Ultrasonic Cardiac Output Monitor) guide in management of fluid refractory pediatric septic shock. Pediatric Respiratory and Critical Care Medicine Association, Annual Scientific Meeting. 2016; proceedings.

Uscom
–
Devices
the
experts
use

10

Products - Uscom BP+

==> picture [120 x 70] intentionally omitted <==

Hypertension, heart failure and vascular disease Central Blood Pressure and Pulse Wave Analysis The new standard for hypertension

• FDA, CE Mark, TGA approvals

• Supra-systolic Oscollometry

• Reliable and

• • accurate

• • Central and

• • Brachial BP

• • Replaces sub-systolic methods (cuff)

• Home or clinic

• PPW Analysis

• • Results in

• 30 seconds

No training required Platform technology with multiple uses

Stand alone, non invasive, accurate, compact system with BP+Reporter

Uscom
–
Devices
the
experts
use

11

Products - Uscom SpiroSonic

Asthma, COPD, Occupational Lung Disease and drug compliance monitoring

• High fidelity digital ultrasonic spirometry

• Multi-path ultrasonic sensing

==> picture [255 x 144] intentionally omitted <==

==> picture [127 x 133] intentionally omitted <==

• FDA, CE, and TGA approvals

• Reliable and accurate

==> picture [41 x 47] intentionally omitted <==

• Auto calibration

• Research, home and clinic

• Wireless transmission

• SpiroReporter analysis software

==> picture [176 x 55] intentionally omitted <==

• FloFree tube – low resistance

• Software guided examination and report

• Simple disinfection

• Platform sensors with medical and industrial applications

Stand alone, non invasive, accurate, compact system with SpiroReporter

12

Uscom
–
Devices
the
experts
use

Future - Big Data

Big data needs high quality sensors Uscom specialises in high quality non-invasive sensors

==> picture [84 x 87] intentionally omitted <==

• Software analytics

==> picture [58 x 61] intentionally omitted <==

• Telemetric signals

• Cloud based processing/diagnosis

• Personalised clinical advice

==> picture [82 x 82] intentionally omitted <==

• Medication and dosage

==> picture [41 x 47] intentionally omitted <==

• Serial monitoring

• Multiple measures

• Home care market

==> picture [58 x 61] intentionally omitted <==

• Subscription service model

==> picture [132 x 126] intentionally omitted <==

• Global partners – China, US, Euro

• Multiple software providers – few hardware providers

Stand alone, wireless, accurate, compact, digital devices

Uscom
–
Devices
the
experts
use

13

Regulatory

Uscom is preparing a new generation of products for regulatory approval across multiple jurisdictions for marketing in 2017

	USCOM 1A	BP+	Uscom BP+	Thor	SpiroSonic
CE (Europe)	✓	✓	Preparation	✓	Preparation
FDA (USA)	✓	✓	Preparation	✓	Preparation
CFDA (China)	✓	-	Preparation	-	Preparation
TGA (Aus)	✓	✓	Preparation	✓	Preparation

Uscom
–
Devices
the
experts
use

14

New US Products

==> picture [263 x 82] intentionally omitted <==

==> picture [172 x 243] intentionally omitted <==

==> picture [173 x 244] intentionally omitted <==

==> picture [172 x 243] intentionally omitted <==

==> picture [172 x 242] intentionally omitted <==

For
launch
FY
2017

15

Uscom
–
Devices
the
experts
use

BioTechnology Leader

==> picture [194 x 99] intentionally omitted <==

==> picture [112 x 111] intentionally omitted <==

Uscom BP+ Thor Granted 12 21 3 Pendin 4 1 1 g Patents
-­‐
Real
IP,
real
value,
product
pipeline

Uscom
–
Devices
the
experts
use

16

CPT Codes and Re-Imbursement

Product	Measure	Region	Code	Price(AUD)	Status
Uscom BP+	Central BP	USA	93050	$25.60	S*
USCOM 1A	Cardiac Output	USA	76999	$107.00	S**
	Cardiac Output	China	310701023	$44.00	✓
	Cardiac Output	China	220600010	$13.50 + $2.50 measure	✓
	Cardiac Output	Australia	TBD	TBD	S**
Uscom Thor	Spirometry	USA	94010	$51.43	✓
	Spirometry	USA	94060	$87.14	✓
	Spirometry	USA	94070	$87.00	✓
	Spirometry	USA	94375	$57.14	✓
	Spirometry	Australia	11506	$20.55	✓
	Spirometry	Australia	11509	$35.65	✓
	Spirometry	Australia	11512	$61.75	✓

S Subject
to
Sonware
modifica,on
and
FDA
no,fica,on S[*] Under
submission TBD
–To
be
determined

De-Risked Technology

Featured in 500+ peer reviewed publications and presentations

==> picture [95 x 126] intentionally omitted <==

==> picture [91 x 108] intentionally omitted <==

==> picture [97 x 112] intentionally omitted <==

==> picture [94 x 116] intentionally omitted <==

==> picture [89 x 106] intentionally omitted <==

==> picture [85 x 104] intentionally omitted <==

==> picture [91 x 103] intentionally omitted <==

==> picture [87 x 102] intentionally omitted <==

==> picture [87 x 104] intentionally omitted <==

==> picture [74 x 99] intentionally omitted <==

Sepsis, Heart failure, Hypertension, Fluid management, Emergency, Pediatrics, Cardiac transplantation, Electrophysiology, Emergency transport, Anesthesia, Liver transplantation, ICU, Pre-eclampsia, Pulmonary hypertension, Nurse outreach, Organ procurement, Haemodialysis, Neonates, infants, Children etc……..

18

Continued Global Growth

Global 1. Uscom
Aus 2. Uscom
UK 3. Uscom
Budapest 4. Uscom
USA

2 • •• ••• •[•] •[•][•] 3 • • • •[•] •[•] •• •

4 •[•] • • • • • • • • • • •

Key
Markets •

1. AsiaPAC
   –
   65% • •

[•] 2/3.
Europe
–
27% 1 4.
Nth
America
–
8%

US
Focus
FY
2017 Stephen
Wilson
–
Former
VP
Corporate Development
Welch
Allyn
appointed

19

China Growth

==> picture [427 x 356] intentionally omitted <==

----- Start of picture text -----

China Health Expenditure as % of GDP
7.9
6.5
5.1 5.0 5.1 [5.4 ]
4.6 [4.8 4.8 4.7 4.7 ]
4.6 4.4 [4.6 ]
2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2018E 2020E
----- End of picture text -----

**David

He
joins
UCM
Board Formerly
J&J
China, McKinsey
Shanghai**

China
Health
Spend (USD) GDP=12,000,000,000,000 Health=5.4%=648,000,000,000 Objec,ve=12%=1,400,000,000,000 Increase=6.6%=792,000,000,000

Uscom
China
Targets (USD) Popula,on
=
1.35b 3
provinces
<
10%
pop
=
$10m 31
Provinces
=
100% 10
x
current
UCM
revenue
=
$10m 2
new
products
=
$20m Total
revenue
China
=
$30m
USD

Uscom positioning to grow with China

20

Growth trend - UCM

**A

blue
sky
story
with
de-­‐risked
operaWons**

==> picture [674 x 279] intentionally omitted <==

----- Start of picture text -----

UCM Revenue and Income
UCM Distribution Agreements
$2,500,000
40 38
$2,039,426
$2,000,000 35
30 27
$1,500,000 $1,377,716
25
$1,010,942 20
$1,000,000
15 12
10
$500,000
5
$0 0
2013 2014 2015 2013 2014 2015
----- End of picture text -----

Current
revenue
only
from
USCOM
1A BP+
and
SpiroSonic
revenue
in
FY
2017

21

Growth trend - UCM

UCM Quarterly Cash Receipts

==> picture [456 x 374] intentionally omitted <==

----- Start of picture text -----

700,000
600,000
500,000
400,000
$
300,000
200,000
100,000
0
Q3 13 Q4 13 Q1 14 Q2 14 Q3 14 Q4 14 Q1 15 Q2 15 Q3 15 Q4 15 Q1 16 Q2 16 Q3 16
Current
revenue
only
from
USCOM
1A
BP+
and
SpiroSonic
revenue
in
FY
2017
----- End of picture text -----

22

Multi-Products

_**Three

world
leading
product
ranges
entering
profit
phase**_

	Three world leading product ranges entering proft phase	Three world leading product ranges entering proft phase	Three world leading product ranges entering proft phase	Three world leading product ranges entering proft phase	Three world leading product ranges entering proft phase	Three world leading product ranges entering proft phase	Three world leading product ranges entering proft phase	Three world leading product ranges entering proft phase	Three world leading product ranges entering proft phase	Three world leading product ranges entering proft phase
		Concept	Product	Pilot	ValidaWon	Regulatory	Revenue	Global DistribuWon	Proft FY17
USCOM 1	A	✓	✓	✓	✓	✓	✓	✓	±✓
Uscom BP	+	✓	✓	✓	✓	✓	✓	✓	±✓
SpiroSoni	c	✓	✓	✓	✓	✓	✓	✓	✓
	Investment to Profit

Investment to Profit

IP
transformed
into
profit

26

Revenue Targets

==> picture [642 x 401] intentionally omitted <==

----- Start of picture text -----

SpiroSonic
–
FY
2017
Total Revenue
20,000,000
18,000,000
16,000,000
BP+
-­‐
FY
2017
14,000,000
12,000,000
SpiroSonic
$ 10,000,000
BP+
USCOM
8,000,000
USCOM
6,000,000
4,000,000
2,000,000
0
2015 2016 2017 2018 2019 2020
----- End of picture text -----*

_**$20m

revenue
by
2020
=
5
year
CAGR
of
58%**_

24

The Future

_**Value

Cascade**_

Comple,on of Capital Raise Products USCOM 1A Uscom BP+ BP+Reporter SpiroSonic Smart Mobile Tube SpiroReporter		Sales New appointments Current distribu,on Thor distribu,on New distribu,on Major partners Re-imbursement US market focus		OperaWons Global opera,ons Increased products Increased scale Cost efec,ve manufacture Revenue growth Proftability		OpportuniWes Share price growth Dividend Transac,on

ConverCng
off
balance
sheet
assets
to
revenue.

25

Uscom

_**Current

ObjecCves**_

• Maintain
USCOM
1A
50+%
growth • Deliver
BP+,
BP+Reporter,
SpiroSonic
and
SpiroReporter
to market • Complete
products,
regulatory
and
manufacturing • Con5nue
discussions • Expand
distribu5on
with
high
reach
partners • Develop
specific
applica5on
partnerships • Consolidate
global
en5ty
and
opera5ons • Manage
rapid
growth

26

Uscom

_**OperaConal

risks**_

• Global medical markets unpredictable

• Product development/regulatory slower and more costly than expected

• Distribution slow to achieve revenue goals and integrate new products

• Capital for acquisitions, product development and production in advance of revenue

• Competition risks and patent breaches – difficult to predict and monitor competitors

• Complexity of operating in multiple jurisdictions – China, US, UK, Hungary, Australia

• Preserving single product revenue growth >50%

• International accounting & auditing expensive, complex and time consuming

• New product lines and new marketing – time to learn

• Transitioning Budapest to volume manufacture

26

Right Sector - Health

ASX 10 yr CAGR % pa

==> picture [439 x 263] intentionally omitted <==

----- Start of picture text -----

14.0
12.1
12.0
10.0
8.0
6.0
3.5
% 4.0
2.0
0.1 0.0
0.0
S&P 200 Financial NAB Materials BHP RMD Healthcare
-2.0 Index (Mining) Index
Index
-2.4
-4.0
-4.5 -4.3
-6.0
----- End of picture text -----

UCM
sales
growth 2014
–
67% 2015
–
59%

• 1[st] Feb
  2006
  –
  1[st] Feb
  2016

• Exclusive
  of
  dividends

Healthcare,
right
sector…..

28

Right Time for Growth

==> picture [587 x 377] intentionally omitted <==

----- Start of picture text -----

Revenue
Growth
%
pa
60
50
40
Uscom
30
Resmed
%
CSL
20
Cochlear
10
0
2013 2014 2015
-10
----- End of picture text -----

Right
company,
right
Cme…..

26

Industry Comparators

Reported and Predicted EBITDA

-1.1 -1.8 -1.1 -1.1 -0.9 -5.15 -2.2 -6.1 1.5 -2.76 -4 -10.1 -12 -10 -8 -6 -4 -2 0 2 4 UCM ACG ADR BP ADR Ed Reported and Predicted EBITDA 2015 2016 2017 • EsC • UCM ACG ADR ADR	-1.1 -1.8 -1.1 -1.1 -0.9 -5.15 -2.2 -6.1 1.5 -2.76 -4 -10.1 -12 -10 -8 -6 -4 -2 0 2 4 UCM ACG ADR BP ADR Ed Reported and Predicted EBITDA 2015 2016 2017 • EsC • UCM ACG ADR ADR	-1.1 -1.8 -1.1 -1.1 -0.9 -5.15 -2.2 -6.1 1.5 -2.76 -4 -10.1 -12 -10 -8 -6 -4 -2 0 2 4 UCM ACG ADR BP ADR Ed Reported and Predicted EBITDA 2015 2016 2017 • EsC • UCM ACG ADR ADR	-1.1 -1.8 -1.1 -1.1 -0.9 -5.15 -2.2 -6.1 1.5 -2.76 -4 -10.1 -12 -10 -8 -6 -4 -2 0 2 4 UCM ACG ADR BP ADR Ed Reported and Predicted EBITDA 2015 2016 2017 • EsC • UCM ACG ADR ADR	-1.1 -1.8 -1.1 -1.1 -0.9 -5.15 -2.2 -6.1 1.5 -2.76 -4 -10.1 -12 -10 -8 -6 -4 -2 0 2 4 UCM ACG ADR BP ADR Ed Reported and Predicted EBITDA 2015 2016 2017 • EsC • UCM ACG ADR ADR
Code	Current Cap Val	Current Price	Target	Target Cap Val
UCM	22m	0.225	0.42	42m
ACG	28m	0.13	0.28	56m
ADR (BP)	75m	0.50	1.19	172m
ADR (Ed)	75m	0.50	1.31	189m

• EsCmates
  *

• • UCM
  -­‐
  Paterson’s, ACG
  -­‐
  Taylor
  Collison

• ADR
  BP
  –
  BellPocer ADR
  Ed
  -­‐
  Edison

30

ASX:UCM

**Share

price
starWng
to
recognise
revenue
growth!**

==> picture [698 x 293] intentionally omitted <==

----- Start of picture text -----

UCM share price Revenue and Income
$3,500,000
$3,100,000
$3,000,000
$2,500,000
$2,039,426
$2,000,000
$1,377,716
$1,500,000
$1,010,942
$1,000,000
$500,000
$0
2013 2014 2015 2016
----- End of picture text -----*

Right
company,
right
Cme…..

9

• Estimate

Research – UCM 2016

==> picture [484 x 344] intentionally omitted <==

==> picture [205 x 52] intentionally omitted <==

2016
year
to
date
performance…..

9

BellDirect 6[h] May 2016

Research – UCM 2016

==> picture [555 x 150] intentionally omitted <==

5[th] Oct 2015 5[th] Oct 2016 12mth Chan e g 0.14c (14m) 0.42c (42m) +200%

12
month
ProjecCons
and
price
and
cap
value
targets

9

Ben Kakoschke – 5[th] October, 2015

Uscom

✓ Value
investment ✓ Experienced
management ✓ Strong
underlying
business ✓ Strong
growth
phase ✓ Invested
in
growth ✓ Premium
global
markets ✓ Diversified
and
lifesaving
technologies ✓ Aggressive
global
growth
strategy ✓ Two
new
product
ranges
for
market
in
the
next
12mths ✓ Right
5me
–
2016
results
imminent

34

Uscom

“Uscom has acquired global assets to ensure reliable revenue growth for investors for the coming decade.”

35

Uscom
–
Medical
devices
the
experts
use

**Uscom

(UCM)
–
Global
Medical
Devices**

Revenue
Growth June
2016

**Thank

You**

Rob Phillips

PhD(med), MPhil(med), FASE, DMU(cardiol) Associate Professor, Critical Care Research Group, School of Medicine, The University of Queensland Executive Chairman/CEO

Uscom
–
Medical
devices
the
experts
use

USCOM 1A Com etitive Advanta p g

Method	Manufacturer	Technology	Rel+Rep	Non- invasive	Simple	Cost	Portable	SV beat to beat
USCOM 1A	Uscom	Doppler	✓	✓	✓	✓	✓	✓
BioZ	Samsung	BioImpedance	✗	✓	✓	✗	✓	✗
NiCOM	Cheetah	BioReactance	✗	✓	✓	✗	✓	✗
Nexfin	Bmeye	APP	✗	✓	✓	✓	✓	✗
CardioQ	Deltex	Doppler	✓	✗	✓	✗	✓	✗
LiDCO	LiDCO	LiCl dilutio +APP	✓	✗	✗	✗	✗	✗
LiDCOrapid	LiDCO	APP	✗	✗	✓	✗	✗	✗
PiCCO (mod Tx + PP)	Pulsion	APP	✓	✗	✗	✗	✗	✗
FloTrac	Edwards	APP	✗	✗	✗	✗	✗	✗
PAC (Tx)	Many	Thermodilution	✗	✗	✗	✗	✗	✗

37

Testimonials

“This
machine
is
saving
lives,
there
are
no
two
ways
about
it.”

Professor
Brendan
Smith,
Anesthe5st,
Intensivist
and
Emergency
Physician,
N.S.W.
Dept
of
Health,
Australia

“USCOM
has
changed
the
way
I
look
at
the
cardiovascular
status
of
my
pa5ents. It’s
part
of
the
ini5al
shock
evalua5on
and
monitored
regularly
thereacer….
USCOM
has
now
been established
as
the
standard
of
care.”

Dr
Akash
Deep,
Director
of
Paediatric
ICU,
King's
College
Hospital,
London

“The
USCOM
device
is
a
simple
method
of
accurately
and
noninvasively
measuring
central
circula5on,
a goal
of
cardiology
for
many
years.
The
device
has
the
poten5al
to
change
the
way
we
approach management
of
sepsis,
heart
failure
and
hypertension.”

Professor
Malcolm
West,
Cardiologist,
Mayne
Professor
of
Medicine
at
The
University
of
Queensland
School
of
Medicine,
Brisbane,
Australia
and
Uscom
Medical
Advisory
Board Member.

“I
have
used
USCOM
for
over
5
years
now
on
our
very
sick
children,
and
use
it
to
guide
management. We
are
now
beginning
mul5-­‐centre,
global
research
which
will
define
the
way
USCOM
is
used
in Paediatric
Departments
across
the
world.”

Dr
Joe
Brierley,
Consultant
Intensivist,
Great
Ormond
Street
Hospital
for
Sick
Children,
London,
UK.

“The
USCOM
device
is
really
good;
I
use
it
in
all
my
aneasthe5cs.
I
think
there
should
be
one
on
every ICU
bed
and
on
every
anaesthe5c
pa5ent.”

Dr
Steve
Woodford,
Consultant
Anaesthe5st,
circulatory
researcher
at
Australian
School
of
Advanced
Medicine,
and
Uscom
Investor,

“To
parents
and
doctors
this
machine,
USCOM,
is
priceless.
This
machine
is
thought
to
have
saved
baby

Abbie’s
life.

BBC
Documentary
“New
machine
helps
save
babies
life”,
2010,
Nolngham
Children’s
Hospital

38

Uscom
–
Medical
devices
the
experts
use

==> picture [163 x 195] intentionally omitted <==

BP+ Competitive Advantage

==> picture [87 x 88] intentionally omitted <==

==> picture [121 x 83] intentionally omitted <==

==> picture [125 x 81] intentionally omitted <==

==> picture [97 x 69] intentionally omitted <==

Uscom BP+	TensioMed	BPLab	IEM	Centron	AtCor
Australia	Hungary	Russia	Germany	UK	Australia
USD 3,500	USD 6,000	USD 7,000	USD 7,000	USD 6,300	USD 20,000
1 min	2 min	2 min	2 min	1 min	1 min
Stand-alone	ABP, needs computer	ABP, needs computer	ABP, needs computer	Stand-alone	Needs computer
CE, FDA, TGA	CE	CE	CE, FDA	CE	CE, FDA
Aortic + brachial waveform	Central systolic BP	Rough waveform	Rough waveform	Rough waveform	Rough waveform
Physical model	Statistical regression	Transfer function	Transfer function	Transfer function	Transfer function

_**Uscom

–
Medical
devices
the
experts
use**_

39

Why ?

_**Independent

research
from
Cambridge
University,
Weill
Cornell, University
of
California,
Wales
Heart
InsCtute
–
BP+
=
Four
stars**_

==> picture [604 x 274] intentionally omitted <==

_**BP+

is
on
the
internaConal
space
staCon**_

36

McEniery CM, Cockcroft JR, Roman MJ, Franklin SS, Wilkinson AB. Central blood pressure: current evidence and clinical importance. Euro Heart J 2014;doi10.1093/ eurojeartj/eht565

SpiroSonic Competitive Advantage

==> picture [139 x 43] intentionally omitted <==

==> picture [112 x 77] intentionally omitted <==

==> picture [88 x 72] intentionally omitted <==

==> picture [90 x 67] intentionally omitted <==

==> picture [74 x 80] intentionally omitted <==

==> picture [70 x 69] intentionally omitted <==

==> picture [82 x 81] intentionally omitted <==

==> picture [68 x 71] intentionally omitted <==

==> picture [92 x 70] intentionally omitted <==

Uscom SpiroSonic	Welch Allyn	Schiller	Sibelmed	Vitalograph	MIR	Carefusion	NDD
Australia	USA	Switzerland	Spain	USA	Italy	USA	Switzerland
SpiroSonic	SpiroPerfect	Spirovit SP-1	Dataspir Touch	Pneumotrac	Spirodoc	Microloop	EasyOne PLus
USD 1,890	USD 2,100	USD 1,850	USD 2,300	USD 2,030	USD 1,580	USD 2,180	USD 1,990
Dual Path Ultrasound	Diff Pressure	Diff Pressure	Turbine	Diff Pressure	Turbine	Turbine	Single Path Ultrasound
Accurate Auto calibration SpiroReporter Fully digital FreeFlo sensor Hygeinic SpO2 Bluetooth Rechargeable	Multiple iterations	Multiple iterations	Multiple iterations	Multiple iterations	Multiple iterations Conssumable turbines	Multiple iterations	Accurate Consumable tube

41

Uscom
–
Medical
devices
the
experts
use